AMPK (AMP-activated protein kinase)

Other Names

5'-adenosine monophosphate-activated protein kinase5'-AMP-activated protein kinase5'-AMP-activated protein kinase catalytic subunit alpha-15'-AMP-activated protein kinase catalytic subunit alpha-25'-AMP-activated protein kinase, catalytic alpha-1 chain5'-AMP-activated protein kinase, catalytic alpha-2 chainAAPK1AAPK2ACACA kinaseAcetyl-CoA carboxylase kinaseAMP-activated protein kinaseAMP-activated protein kinase, catalytic, alpha-1AMPKAMPK alpha 1AMPK alpha 2AMPK subunit alpha-1AMPK subunit alpha-2AMPK-alpha-2 chainAMPK1AMPK2AMPKa1AMPKA2HMGCR kinaseHydroxymethylglutaryl-CoA reductase kinasePRKAAPRKAA1PRKAA2PRKAB1PRKAB2PRKAG1PRKAG2PRKAG3protein kinase AMP-activated catalytic subunit alpha 1protein kinase AMP-activated catalytic subunit alpha 2protein kinase, AMP-activated, alpha 1 catalytic subunitprotein kinase, AMP-activated, alpha 2 catalytic subunitSnf1SNF1 (Saccharomyces cerevisiae ortholog)Sucrose NonFermenting 1 kinaseTau-protein kinase P

Synopsis

AMP-Activated Protein Kinase (AMPK): A Comprehensive Reference

1. Identity and Overview

AMP-activated protein kinase (AMPK) is not itself a botanical extract or a single dietary supplement ingredient; it is an endogenous enzyme — a serine/threonine protein kinase — present in virtually all eukaryotic cells. In the context of dietary supplements and natural medicine, "AMPK" typically refers to the cellular target that a class of natural compounds is intended to activate, and the term is increasingly used in commercial contexts as shorthand for supplements, foods, and botanical preparations that modulate this enzyme's activity.

AMPK is a serine/threonine protein kinase complex consisting of a catalytic α-subunit (α1 and α2), a scaffolding β-subunit (β1 and β2), and a regulatory γ-subunit (γ1, γ2, and γ3). The classical role of AMPK is as a cellular energy sensor activated by falling energy status, signaled by increases in AMP to ATP and ADP to ATP ratios. AMPK is a highly conserved sensor of cellular energy that appears to have arisen at an early stage during eukaryotic evolution.

AMPK is an evolutionarily conserved serine/threonine kinase involved in the homeostasis of cellular energy, and it has developed as an appealing clinical target for the diagnosis and potential treatment of multiple metabolic diseases such as diabetes mellitus, obesity, inflammation, and cancer.

The full systematic name of the enzyme is 5'-AMP-activated protein kinase (EC 2.7.11.31). It is also referred to in the literature as hydroxymethylglutaryl-CoA reductase kinase in early publications, reflecting its original characterization through its regulation of lipid metabolism.

Common Forms and Supplement Preparations

Because AMPK is an endogenous enzyme rather than an ingested molecule, dietary supplement products targeting AMPK are formulated around natural compounds that activate it. The most widely studied natural AMPK activators, available in commercial supplement form, include:

Berberine (isoquinoline alkaloid from Coptis chinensis, Berberis vulgaris, and related species) — typically in capsule or tablet form, standardized to berberine HCl content.
Gynostemma pentaphyllum (jiaogulan) extract — available as dried leaf, tea, and standardized extracts (e.g., heat-processed "actiponin" preparations).
Resveratrol (stilbene polyphenol from Vitis vinifera and other plants) — capsules and tablets, often standardized to trans-resveratrol.
Quercetin (flavonoid from many fruits and vegetables) — capsules, often combined with bromelain or other absorption enhancers.
Epigallocatechin-3-gallate (EGCG) (flavan-3-ol from Camellia sinensis) — green tea extracts, standardized capsules.
Curcumin (from Curcuma longa) — capsules, often with piperine or lipid-based delivery systems for bioavailability.

A wide variety of natural products — many derived from plants used as herbal medicines in Asian countries — have been reported to activate AMPK. These include resveratrol from red grapes, quercetin present in many fruits and vegetables, ginsenoside from Panax ginseng, curcumin from Curcuma longa, berberine from Coptis chinensis (used in the Chinese herbal medicine Huanglian), and epigallocatechin gallate from green tea.

2. Traditional and Historical Use

Because AMPK as a molecular entity was not identified until the late twentieth century, there is no traditional use of "AMPK" per se. However, the botanical ingredients now recognized as AMPK activators have long individual histories of use across multiple medical traditions.

Berberine and Coptis chinensis (Huanglian)

Coptidis rhizome (CR), also known as Huanglian in Chinese, is the rhizome of Coptis chinensis Franch. Rhizoma Coptidis is a popular traditional Chinese herb used for treatment of inflammation and diabetes, and contains 5.2%–7.7% of berberine. The anti-diabetes activity of Rhizoma Coptidis is documented as early as 1500 years ago. However, Rhizoma Coptidis was usually used to treat infection or inflammation, since diabetes was not prevalent in ancient times.

Berberine, extracted from Berberis vulgaris (root), was an ancient herbal medicine used in treating diarrhea. Rhizoma Coptidis is an herb that has been frequently used in many traditional formulas for the treatment of diabetes mellitus over thousands of years. Berberine, the main active component of Rhizoma Coptidis, has been demonstrated to have the potential effect of hypoglycemia.

Gynostemma pentaphyllum (Jiaogulan)

Gynostemma pentaphyllum is a herbaceous vine of the family Cucurbitaceae (cucumber or gourd family) that is indigenous to and widely used in Asian countries including Korea, China, and Japan as traditional medicines or tea. The oriental traditional medicinal herbal plant Gynostemma pentaphyllum has shown a wide range of beneficial effects on glucose and lipid metabolism. The plant has been traditionally consumed as an herbal tea (known as "Jiaogulan tea") and used in East Asian medicine as an adaptogen and tonic for longevity, fatigue resistance, and cardiovascular support, particularly in Guizhou province of China.

Metformin's Botanical Precursor: Galega officinalis

Metformin — a pharmaceutical AMPK activator and first-line type 2 diabetes drug — is derived from guanidine compounds found in Galega officinalis (French lilac or goat's rue). AMPK is activated by several natural plant products derived from traditional medicines. One of these is salicylate, probably the oldest medicinal agent known to humankind. In 2001 it was shown that AMPK is activated by metformin, currently the major drug for treatment of type 2 diabetes.

Other Botanical Sources

Momordica charantia, commonly known as bitter melon, has been used as a dietary supplement throughout the last centuries in the management of diabetes. Bitter melon has traditional use in South Asian (Ayurvedic), Chinese, and Caribbean medicinal systems for blood sugar regulation, and modern research has identified AMPK activation among its potential mechanisms.

3. Key Constituents and Active Compounds

The AMPK Complex: Structural Components

In most species, AMPK exists as an obligate heterotrimer, containing a catalytic subunit (α) and two regulatory subunits (β and γ). Ubiquitous expression of AMPKα1-, β1-, and γ1-subunits in many tissues makes the α1β1γ1 complex a reference for AMPK assays to identify AMPK activators.

Natural Compounds Targeting AMPK

Berberine is an isoquinoline alkaloid. Berberine has been shown to inhibit mitochondrial respiratory complex I, which could lead to the increase of AMP and subsequent AMPK activation. However, the relationship is not fully linear: a recent report demonstrates that berberine blocks complex I, leading to increases in glucose consumption and lactate release, which is independent of AMPK. This raises an interesting possibility that berberine and metformin may act through similar mechanisms despite different structure and transporters. Additionally, berberine activated lysosomal AMPK; AXIN1 mediated berberine's effect on lysosomal AMPK activation, while PEN2 did not. Berberine, but not metformin, decreased UHRF1 expression by promoting its degradation.

Damulin A and B are dammarane-type saponins specific to Gynostemma pentaphyllum. G. pentaphyllum contains two novel dammarane-type saponins designated as damulin A and damulin B that strongly activate AMPK in cultured L6 myotube cells. Damulins A and B also increased β-oxidation and glucose uptake with increasing GLUT4 translocation to the plasma membrane in L6 myotube cells.

Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a polyphenol found in grape skins, red wine, and Japanese knotweed (Polygonum cuspidatum). Research has investigated the effects of resveratrol and EGCG on lipid synthesis in liver cells; the results showed that both resveratrol and EGCG can inhibit cholesterol synthesis in liver cells by activating AMPK.

Quercetin is a flavonoid ubiquitous in plant foods. Quercetin increased AMPK, insulin receptor substrate 1 (IRS-1), and AS160 phosphorylation in basal conditions and glycogen synthase kinase 3 (GSK3β) in insulin-stimulated conditions. Quercetin usually occurs in plants as glycosides, linked with various sugar moieties, mostly glucose, but also galactose, rhamnose, and others.

EGCG (epigallocatechin-3-gallate) is the principal catechin in green tea. Catechins, and particularly EGCG, are predominantly absorbed in the jejunum and the ileum via paracellular diffusion through epithelial cells without any de-conjugation or hydrolysis.

Among other compounds, flavonoids found in natural sources, like quercetin, genistein, epigallocatechins, and resveratrol, have been proposed as AMPK activators.

4. Established Mechanisms of Action

Canonical (AMP/ADP-Dependent) Activation

AMPK is hypothesized to be activated by a two-pronged mechanism. Under lowered intracellular ATP levels, AMP or ADP can directly bind to the γ regulatory subunits, leading to a conformational change that protects the activating phosphorylation of AMPK. Kinetic enzyme assays have shown that allosteric activation by AMP results in a greater than 10-fold increase in activity, while the activation resulting from Thr-172 phosphorylation of the α-subunit is greater than 100-fold.

In addition to nucleotide binding, phosphorylation of Thr172 in the activation loop of AMPK is required for its activation, and several groups have demonstrated that the serine/threonine kinase LKB1 directly mediates this event. Ca²⁺/calmodulin-dependent kinase β (CaMKKβ) phosphorylates Thr-172 in response to increased cytosolic Ca²⁺ concentrations independent of changes in adenine nucleotides.

Non-Canonical Activation Pathways

Recently described non-canonical pathways include those by which AMPK senses the availability of glucose, glycogen, or fatty acids, and by which it senses damage to lysosomes and nuclear DNA.

Downstream Effects on Metabolism

Once activated, AMPK acts to restore energy homeostasis by promoting ATP-producing catabolic pathways while inhibiting energy-consuming processes.

Carbohydrate metabolism: AMPK regulates carbohydrate metabolism by increasing GLUT4-dependent glucose uptake through phosphorylation of the Rab-GTPase-activating proteins AS160/TBC1D1 and by increasing the glycolysis-stimulator fructose-2,6-bisphosphate concentrations through phosphorylation of specific 6-phosphofructose-2-kinase isoforms. AMPK activation in the liver also results in the downregulation of the gluconeogenic genes glucose-6-phosphatase and phosphoenolpyruvate carboxykinase (PEPCK) through multiple mechanisms.

Lipid metabolism: In skeletal muscle, once AMPK becomes activated, it exerts control in part by regulating fatty-acid oxidation through the phosphorylation of acetyl-CoA carboxylase 2 (ACC2) and mitochondrial biogenesis through increasing the expression of proteins vital for proper mitochondrial function such as citrate synthase and succinate dehydrogenase.

mTORC1 suppression and autophagy: The most thoroughly described mechanism by which AMPK regulates cell growth is via suppression of the mammalian target of rapamycin complex 1 (mTORC1) pathway. One mechanism by which AMPK controls mTORC1 is by direct phosphorylation of the tumor suppressor TSC2 on serine 1387.

Mitochondrial biogenesis and PGC-1α: Activation of AMPK in skeletal muscle increases glucose uptake, fatty acid oxidation, and mitochondrial biogenesis by increasing gene expression in these pathways. The peroxisome-proliferator-activated receptor gamma coactivator 1α (PGC-1α) has emerged as a master regulator of mitochondrial biogenesis; PGC-1α gene expression is induced by exercise and by chemical activation of AMPK in skeletal muscle. Direct phosphorylation of PGC-1α at threonine-177 and serine-538 by AMPK is required for the PGC-1α-dependent induction of the PGC-1α promoter, and these phosphorylations initiate many of the important gene regulatory functions of AMPK in skeletal muscle.

Cancer-related pathways: The mechanisms by which AMPK could inhibit cell growth and exert a tumor-suppressive role include: suppressing fatty acid and cholesterol biosynthesis through direct phosphorylation of ACC1, HMGR, and other substrates; inhibition of protein synthesis by phosphorylation of mTORC1 and EF2K; and promoting cell-cycle arrest and apoptosis by stabilizing p53 and regulating cyclin-dependent kinase.

Anti-inflammatory effects: Research indicates that AMPK levels are suppressed by overeating, triggering insulin resistance and hence diabetes. Reducing AMPK levels can also induce chronic inflammation, a critical component of diseases like diabetes and cancer. Combined interventions with plant-derived bioactives and exercise enhance AMPK phosphorylation, mitochondrial biogenesis, glucose uptake, and lipid oxidation while reducing pro-inflammatory cytokines (e.g., TNF-α, IL-6) and NF-κB signaling via SIRT1/PGC-1α/Nrf2 pathways.

5. Scientific Evidence by Area of Use

5.1 Glucose Regulation and Type 2 Diabetes

This is the area with the strongest human clinical evidence for AMPK-activating supplements.

Berberine — Clinical Evidence (Strongest): Fifty studies involving 4,150 participants have been included in recent meta-analyses. Berberine alone significantly reduced fasting plasma glucose (FPG) (MD = −0.59 mmol/L), 2-hour postprandial blood glucose (2hPBG) (MD = −1.57 mmol/L), and low-density lipoprotein cholesterol (LDL-C) (MD = −0.30 mmol/L).

Forty-six trials were assessed in one systematic review, with analysis revealing significant reductions in HbA1c (MD = −0.73; 95% CI [−0.97, −0.51]), FPG (MD = −0.86, 95% CI [−1.10, −0.62]), and 2hPG (MD = −1.26, 95% CI [−1.64, −...]) in patients treated with berberine alone or with standard diabetic therapies versus the control group.

Compared with lifestyle modification with or without placebo, the co-intervention of berberine and lifestyle modification showed significantly hypoglycemic and antidyslipidemic responses. Compared with oral hypoglycemics including metformin, glipizide, or rosiglitazone, berberine did not demonstrate significantly better glycemic control but showed a mild antidyslipidemic effect.

A randomized, double-blind, placebo-controlled, two-period crossover, single-dose, Phase 1 clinical trial (NCT03972215) demonstrated that berberine enhances glucose-stimulated insulin secretion in humans without altering basal insulin levels.

Evidence quality note: Methodological quality of included RCTs was generally assessed as low. At this point, there are few multicenter clinical trials to confirm the hypoglycemic action in a larger number of patients. The scientific evidence that berberine is as effective as other conventional treatments in treating type 2 diabetes mellitus remains to be further validated. The safety of long-term berberine intake for the chronicity of diabetes also remains uncertain.

Gynostemma pentaphyllum — Clinical Evidence (Moderate): A 12-week, randomized, double-blind, placebo-controlled trial investigated the effects of actiponin, a heat-processed Gynostemma pentaphyllum extract, on body weight, fat loss, and metabolic markers of Korean participants. This randomized double-blind placebo-controlled crossover study provided placebo or 450 mg of G. pentaphyllum dried leaf extract equivalent to 2.25 g of dry leaf per day for four weeks to 16 healthy untrained young males. Following 4-week supplementation, participants had significantly lower leptin and blood glucose levels and improved time trial performance over 20 km, which corresponded with higher muscle oxygen flux compared to placebo.

Resveratrol and Quercetin — Preliminary/In Vitro Evidence: Both resveratrol and quercetin increased insulin-stimulated glycogen synthesis and reduced lactate production in human myotubes. Thus, physiological doses of resveratrol or quercetin may exhibit anti-diabetic actions in human myotubes. However, much of this evidence is from cell studies or animal models; consistent positive results in full human RCTs are lacking for these compounds specifically as AMPK activators.

Genetic and pharmacological studies indicate that AMPK is needed in response to glucose deficiency, dietary restriction, and increased physical activity for preserving glucose homeostasis.

5.2 Obesity and Body Composition

Berberine activates AMPK to reduce fat production and body fat ratio, improves insulin sensitivity, and promotes glucose transport. Collectively, these effects cause the fat and sugar in patients with metabolic disorders to change from accumulation to decomposition.

Meta-analytic conclusions report that berberine can improve obesity and hyperlipidemia by reducing TG, TC, and LDL and increasing HDL, and reduce insulin resistance to improve type 2 diabetes.

For Gynostemma, the human randomized trial using the actiponin extract found reductions in abdominal and total fat, though the trials are small in scale. These activities likely overlap with diverse downstream effects of AMPK activation.

AMPK is involved in a wide range of biological activities that normalizes lipid, glucose, and energy imbalances. These pathways are dysregulated in patients with metabolic syndrome (MetS), which represents a clustering of major cardiovascular risk factors including diabetes, lipid abnormalities, and energy imbalances.

5.3 Lipid Metabolism and Dyslipidemia

Ongoing experimental and clinical studies have illuminated great potential of berberine in regulation of glucose and lipid homeostasis, cancer growth, and inflammation. Furthermore, the lipid-lowering effect of berberine is comparable to those of conventional lipid drugs but with low toxicity.

Total extracts or saponins from G. pentaphyllum have been shown to exert a wide range of beneficial effects such as reducing cholesterol and blood glucose levels, strengthening immunity, and inhibiting cancer growth.

5.4 Cardiovascular Health

AMPK confers cardioprotective effects by preventing endothelial and vascular dysfunction, and by controlling or regulating oxidative stress and inflammatory processes. For AMPK, sex-specific effects have been reported, influencing metabolic and cardiovascular responses. Exercise and metabolic stress generally cause higher AMPK activity in males. At the same time, females exhibit protective mechanisms against insulin resistance or oxidative stress, particularly in conditions like obesity.

Human clinical trial evidence for natural AMPK activators in cardiovascular endpoints specifically is limited. In one study, 84 male and female patients with coronary artery disease were enrolled to evaluate the beneficial effects of crocin (an active compound in saffron). Patients received crocin 30 mg/day, saffron aqueous extract 30 mg/day, or placebo for 4 weeks. Significantly enhanced expression/activity of SIRT1 and AMPK, and decreased expression of LOX1 and NF-κB, were observed in the crocin-treated group compared with the placebo group.

Most natural cardioprotective agents that activate AMPK have only been evaluated in animal models and in vitro studies. Human cardiovascular outcome trials for AMPK-activating supplements are largely absent.

5.5 Cancer Biology

Current evidence suggests that AMPK can act as a tumor suppressor by modulating inflammation, opposing metabolic changes that occur during tumorigenesis, and directly inducing cell-cycle arrest.

Literature review suggests the deregulation of cellular metabolism to be one of the key drivers of tumorigenesis and cancer progression. Recent reports state that AMPK plays a central role in tumor cellular bioenergetics and in evoking an anti-tumor immune response, owing to its molecular crosstalk with various key players of the tumor microenvironment.

Evidence quality note: The cancer-related evidence for natural AMPK activators is overwhelmingly preclinical (cell lines and animal models). Researchers suggest that AMPK activators are potentially useful for the treatment of conditions such as obesity, type 2 diabetes, and cancer, and that combining different AMPK activators in different clinical contexts might provide optimal treatment. However, they conclude that more research is needed to determine the precise mechanisms of action of AMPK activators and thereby optimize treatment strategies.

5.6 Exercise Performance and Skeletal Muscle

AMPK, a metabolic regulator that senses low energy availability and controls mitochondrial dynamics, is needed for exercise to maintain physical fitness with age and can recapitulate this exercise benefit.

Muscle AMPK Thr172 phosphorylation significantly increased after 60 minutes of exercise following G. pentaphyllum supplementation. AMPK Thr172 phosphorylation levels relative to total AMPK increased earlier following exercise with G. pentaphyllum compared to placebo. This was observed in a small human RCT (n=16 males).

Regular exercise systematically remodels mitochondrial quality control structure and function by integrating signaling axes such as AMPK, SIRT1, and p38 MAPK, thereby promoting coordinated mitochondrial renewal and partially reversing aging-associated mitochondrial dysfunction.

5.7 Aging and Longevity

Recent studies have demonstrated a strong relationship between aging-associated reductions in mitochondrial function, dysregulated intracellular lipid metabolism, and insulin resistance. Given the important role of AMPK in the regulation of fat oxidation and mitochondrial biogenesis, examination of AMPK activity in young and old rats found that acute stimulation of AMPKα2 activity by AICAR and exercise was blunted in skeletal muscle of old rats.

These results suggest that aging-associated reductions in AMPK activity may be an important contributing factor in the reduced mitochondrial function and dysregulated intracellular lipid metabolism associated with aging.

AMPK is a key player in autophagy and mitophagy during starvation and aging, and its activation in skeletal muscle appears to be diminished by aging.

Evidence quality note: The bulk of aging-related AMPK evidence remains preclinical. No large human longevity trials using natural AMPK activators have been completed. The connection to longevity in humans is extrapolated from animal models and mechanistic studies.

5.8 Inflammation and Immune Modulation

AMPK regulates energy homeostasis and immune responses, making it a key target for immunometabolic disorders like obesity, insulin resistance, and neurodegenerative diseases. Aberrancy in AMPK signaling is one of the determining factors which lead to the development of chronic diseases such as obesity, inflammation, diabetes, and cancer.

Polyphenolic compounds, including quercetin, EGCG, resveratrol, and curcuminoids, exhibit multifaceted immunoregulatory actions by modulating key age-related intracellular pathways such as AMPK, Sirtuin 1 (SIRT1), mechanistic target of rapamycin (mTOR), and NF-κB.

Human evidence for anti-inflammatory effects specifically mediated through AMPK activation by dietary supplements is limited; most data come from cell and animal studies, with downstream markers (CRP, IL-6, TNF-α) measured as secondary outcomes in metabolic trials.

5.9 Nonalcoholic Fatty Liver Disease (NAFLD)

The role of AMPK in nonalcoholic steatohepatitis (NASH) and other disorders where therapeutic targeting may exert beneficial effects is actively discussed in the scientific literature. Meta-analyses of berberine also include nonalcoholic fatty liver disease (NAFLD) among the metabolic disorders evaluated. Evidence from human trials is still emerging and is considered preliminary.

6. Body Systems and Health Areas Associated with AMPK

Metabolic/Endocrine System: Glucose homeostasis, insulin sensitivity, diabetes prevention and management, lipid regulation, fat oxidation, and metabolic syndrome.
Skeletal Muscle: Glucose uptake, fatty acid oxidation, GLUT4 translocation, mitochondrial biogenesis, and exercise adaptation.
Liver: Gluconeogenesis suppression, fatty acid synthesis inhibition, lipid storage regulation, and NAFLD/NASH.
Cardiovascular System: Endothelial function, oxidative stress modulation, inflammation suppression, and cardiac energy metabolism.
Adipose Tissue: Fat accumulation, energy expenditure, and adipokine signaling.
Central Nervous System: Hypothalamic energy sensing, food intake regulation, and neuronal energy balance.
Immune System: Macrophage polarization, NF-κB regulation, and inflammatory cytokine modulation.
Cancer Biology: Cell-cycle arrest, autophagy induction, and tumor suppression (preclinical evidence only).
Aging/Longevity Pathways: Mitophagy, mitochondrial quality control, and autophagy — primarily preclinical evidence.

AMPK is a serine/threonine protein kinase that functions to maintain the balance between ATP production and consumption in most eukaryotic cells. It plays a relevant role in regulating cellular metabolism, preserving cellular energy homeostasis, and is involved in many other cellular processes, including cell cycle regulation and endothelial and vascular relaxation.

7. Dosage Forms and Reported Dosages

The following dosages are drawn exclusively from clinical studies or systematic reviews as explicitly cited:

Berberine

In multiple randomized controlled trials of berberine as an AMPK-activating agent in metabolic disorders, typical dosing was 900 to 1,500 mg per day given in divided doses, usually 500 mg two or three times daily. The most well-known berberine trial, published in the journal Metabolism, followed patients for 3 months at 500 mg three times daily. Key safety findings included no liver damage observed and no kidney damage observed, while 34.5% of patients experienced transient GI side effects (mild and temporary) and nearly a quarter (24.1%) needed their dose reduced because GI symptoms were intolerable. The researchers concluded berberine has a favorable safety profile at this dose.

Gynostemma pentaphyllum

In the randomized double-blind placebo-controlled crossover study in healthy young males, 450 mg of G. pentaphyllum dried leaf extract (equivalent to 2.25 g of dry leaf per day) was used for four weeks. The 12-week randomized obesity trial (actiponin) also used a standardized extract preparation, though the specific milligram dose is not extractable from available summaries without access to the full text.

Quercetin

In a randomized clinical trial examining 84 women with polycystic ovary syndrome (PCOS), the treated group was administered 1 g of quercetin daily for 12 weeks. Quercetin supplements increased the expression of the ADIPOR1 and ADIPOR2 transcript and improved the AMPK level by 12.3% when compared to the control group.

Crocin (from Saffron)

In a study of 84 patients with coronary artery disease, one group received a crocin capsule of 30 mg/day daily and another group received a saffron aqueous extract capsule of 30 mg/day daily, while a third group received placebo capsules for 4 weeks.

Resveratrol (In Vitro Reference Dose)

In cell studies using human primary myotubes, cultures were treated for 24 hours with either 0.1 μM of resveratrol (RSV) or with 10 μM of quercetin (Q). These are in vitro physiological concentrations and do not directly correspond to supplemental oral dosing in humans.

8. Safety Considerations and Drug Interactions

General Considerations

Supplements acting on AMPK pathways are not automatically benign. Some AMPK-acting botanicals affect liver enzymes and transporters that control drug metabolism, such as cytochrome P450 isoenzymes and P-glycoprotein. If these pathways are altered, levels of co-administered drugs can rise or fall — especially important for medicines with narrow therapeutic windows like anticoagulants, certain heart medicines, or some psychiatric drugs. Product quality and standardization affect this risk because unstandardized preparations may contain variable amounts of active compounds.

Hypoglycemia Risk

When people combine an AMPK activator with insulin or sulfonylureas, the risk of hypoglycemia can increase. Metformin alone rarely causes severe hypoglycemia, but adding berberine or another glucose-lowering botanical to existing antidiabetic drugs can push blood sugar too low.

Berberine-Specific Safety Data

Laboratory and limited human studies suggest berberine may affect several cytochrome P450 enzymes in the liver — particularly CYP3A4, CYP2D6, and CYP2C9 — which are responsible for metabolizing numerous prescription medications. It may also influence P-glycoprotein, a protein that transports drugs out of cells.

No serious adverse effects from berberine were reported in a systematic review covering 14 randomized trials involving 1,068 participants.

Berberine is contraindicated during pregnancy and breastfeeding. It crosses the placenta and can displace bilirubin from albumin in fetal blood, potentially causing kernicterus (a type of brain injury in newborns from bilirubin buildup). The NCCIH explicitly states that berberine is "likely to be unsafe for infants."

No evidence of liver damage has been found in any published clinical trial at standard doses, and the NIH's LiverTox database classifies berberine as an unlikely cause of clinically apparent liver injury.

Interaction with Metformin

Berberine and metformin possess similar pharmacological activities with respect to hypoglycemic/hypolipidemic effects, anti-inflammation, and anti-cancer actions. AMPK is the key regulatory protein mediating the action of both berberine and metformin. Both BBR and metformin activated AMPK indirectly by inhibiting respiratory complex I and elevating cellular AMP/ATP. However, the potent glucose-lowering effects with minimal hypoglycemia of berberine and metformin may be partially due to their bidirectional regulation of the AMPK signaling pathway.

Potential for Excessive AMPK Activation

Since AMPK activation is a signal of cellular energy stress, keeping it constantly "on" can confuse the body's feedback systems. Just as chronically elevated cortisol or adrenaline would cause downstream dysfunction, a constantly activated AMPK signal can result in biological fatigue or adaptation. Over time, the pathway becomes less responsive, and its intended effects — like mitochondrial biogenesis, glucose uptake, or autophagy — start to plateau.

Complexity of AMPK's Role in Cancer

AMPK has a complex role in cancer tumor microenvironments. While preclinical evidence supports a tumor-suppressive role, the full picture in human cancer remains incompletely understood, and no natural AMPK activator is approved or established as a cancer treatment or chemoprevention agent.

Lack of Long-Term Safety Data

For most natural AMPK-activating supplements, safety data beyond 3–6 months is sparse. The majority of human trials are short-duration (4 to 24 weeks), and it is not certain about the safety of long-term berberine intake for the chronicity of diabetes.

References

Health Conditions

Health conditions that AMPK (AMP-activated protein kinase) may help support.

Cellular Energy SupportScientific
AMPK (AMP-activated protein kinase) is the master regulator of cellular energy homeostasis, activated when cellular ATP is depleted and AMP rises. Its activation promotes mitochondrial biogenesis, glucose uptake, fatty acid oxidation, and inhibits energy-consuming anabolic processes to restore cellular ATP balance.
Insulin Sensitivity SupportScientific
AMPK is a key intracellular energy sensor and master regulator of glucose metabolism. Its activation stimulates glucose uptake via GLUT4 translocation, increases fat oxidation, improves mitochondrial function, and suppresses hepatic gluconeogenesis—all mechanisms that improve insulin sensitivity. It is a recognized pharmacological target for insulin resistance and T2DM.
MetabolismScientific
AMPK is a well-established master regulator of cellular energy and metabolism, activated when the AMP/ATP ratio rises during energy stress. It simultaneously suppresses anabolic (energy-consuming) pathways and activates catabolic (energy-producing) pathways, including glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. Clinical evidence from human skeletal muscle studies and metformin trials confirms that AMPK activation translates into measurable improvements in glucose and lipid metabolism.
Mitochondrial HealthScientific
AMPK is listed as a supplement/activator form representing AMPK-activating compounds that target mitochondrial biogenesis. AMPK activation is the central signaling node that drives PGC-1α-mediated mitochondrial biogenesis and mitophagy in response to energy stress.

Body Systems

Body systems that AMPK (AMP-activated protein kinase) may help support.

No body systems available.